Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

BNT327

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BioNTech, Biotheus

Drug class:

PD-L1 inhibitor, VEGF-A inhibitor

Related drugs:

‹

Pusintin (bevacizumab biosimilar) (0)

TRS003 (bevacizumab biosimilar) (0)

HD204 (bevacizumab biosimilar) (0)

bevacizumab biosimilar (0)

hVEGF26–104/RFASE (0)

atezolizumab (236)

durvalumab (198)

sugemalimab (7)

envafolimab (6)

IO102-IO103 (4)

atezolizumab/hyaluronidase (1)

CF33-hNIS-antiPDL1 (0)

PD-L1.t-haNK (0)

PF-07257876 (0)

bevacizumab (416)

Aybintio (bevacizumab biosimilar) (14)

bevacizumab-maly (12)

bevacizumab-awwb (11)

bevacizumab-adcd (11)

bevacizumab-tnjn (8)

bevacizumab-bvzr (8)

Krabeva (bevacizumab biosimilar) (7)

Byvasda (bevacizumab biosimilar) (4)

ziv-aflibercept IV (4)

SIBP-04 (bevacizumab biosimilar) (1)

BP102 (bevacizumab biosimilar) (0)

SCT510 (bevacizumab biosimilar) (0)

Ankada (bevacizumab biosimilar) (0)

BI 695502 (bevacizumab biosimilar) (0)

MIL 60 (bevacizumab biosimilar) (0)

LY01008 (bevacizumab biosimilar) (0)

CBT124 (bevacizumab biosimilar) (0)

Cizumab (bevacizumab biosimilar) (0)

Equidacent (bevacizumab biosimilar) (0)

GB222 (bevacizumab biosimilar) (0)

HLX-04 (bevacizumab biosimilar) (0)

ranibizumab (0)

Pusintin (bevacizumab biosimilar) (0)

TRS003 (bevacizumab biosimilar) (0)

HD204 (bevacizumab biosimilar) (0)

bevacizumab biosimilar (0)

hVEGF26–104/RFASE (0)

›

PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	BNT327 Sensitive: C2 – Inclusion Criteria BNT327 Sensitive : C2	BNT327 Sensitive: C2 – Inclusion Criteria BNT327 Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	BNT327 Sensitive: C3 – Early Trials BNT327 Sensitive : C3	BNT327 Sensitive: C3 – Early Trials BNT327 Sensitive : C3